Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple Myeloma Background of the Study: Exportin 1 (XPO1) mediates the nuclear export and functional inactivation of tumor suppressor proteins (TSPs), is associated with poor prognosis in MM, and contributes to proteasome inhibitor (PI) and immunomodulatory drug (IMiD) resistance. Selinexor (SEL) is a novel, oral, […]

CAR T-Cell Therapy for Multiple Myeloma Keith Stewart, MB, ChB; Saad Z. Usmani, MD; Thomas G. Martin, MD; Sagar Lonial, MD; Ivan M. Borrello, MD; and Gareth Morgan, MD, PhD, highlight trials that are reviewing the potential use of chimeric antigen receptor T-cell therapy that targets the protein, B-cell maturation antigen in multiple myeloma.

Optimizing multiple myeloma treatment Jesús San Miguel, MD, PhD, University of Navarra Clinic, Pamplona, Spain, talks on the importance of having access to optimal tools, such as measurable …

Daratumumab in the treatment of multiple myeloma Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the use of daratumumab in the treatment of multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Daratumumab is the frontline in monoclonal antibody treatment in multiple myeloma. It is […]